A man is examined by a doctor


Early access to AstraZeneca investigational medicinal products

We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.

Information on Early Access to AstraZeneca Investigational Medicinal Products (PDF 334kb)


Looking for information about our medicines?

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask your health professional for advice about medicines.

Are you in the US and looking for our patient prescription assistance programmes?

Sharing clinical trials information

We publish information about the registration and results (whether favourable or not to AstraZeneca) of all new and ongoing clinical trials for all products in all phases - including marketed medicines, drugs in development and drugs whose further development has been discontinued.

What does it take to find a new medicine?

It takes time – more than 10 years. It takes money – up to $1 billion before the first sales are made. But most importantly, it takes skill, experience and collaboration – working with our stakeholders and our partners to identify needs and meet them with medicines that make a real difference.